Handheld red‑light optical scan to help diagnose skin lesions
Official title: Assessment of Novel Label-free Optical Imaging Technology for the Evaluation of Skin Lesions
Run by Emory University · NCT07213154 · Data updated 2026-11-12
This trial tests a handheld red‑light optical scan (qOBM) to see if it helps doctors diagnose skin cancer in adults with skin lesions.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 10 (estimated) |
| Sponsor | Emory University Academic / other |
| Drugs / interventions | radiation |
| Locations | 2 sites (Atlanta, Georgia and 1 other locations) |
| Status | Recruiting |
| Started | October 15, 2025 |
| Main results expected | September 17, 2026 |
| Study ends | September 17, 2027 |
| Registry record updated | December 16, 2025 |
| Trial ID | NCT07213154 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older with skin lesions, including suspected melanoma or dysplastic nevi, who can give informed consent and have not had prior surgery or radiotherapy to the area are ideal candidates.
✕Probably not a fit
People under 18, or those who have had prior surgery or radiation to the area being imaged, are excluded and are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This first‑in‑human study uses a handheld quantitative oblique back‑illumination microscopy (qOBM) device that noninvasively images skin lesions with red light in situ and in vivo. Adult patients with a range of skin lesions, including suspected melanoma or dysplastic nevi, will undergo qOBM imaging and some may receive additional scans as determined by their physician. When lesions are biopsied or surgically removed, optical findings will be compared with histology to characterize features such as lesion margins, depth, pigmentation, and changes in surrounding tissue. Secondary aims include cataloguing malignant, benign, and inflammatory lesion appearances and documenting pre‑ and post‑treatment tissue changes.
Why it matters
Potential benefit: If successful, qOBM could provide a quick, noninvasive way to distinguish malignant from benign skin lesions and reduce unnecessary biopsies and procedures.
How similar studies have gone: This is the first‑in‑human test of qOBM specifically, although other optical imaging techniques such as reflectance confocal microscopy and optical coherence tomography have shown promise in aiding skin lesion diagnosis.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male or Female * Candidate with skin lesions * Signed study-specific informed consent prior to study entry * ≥ 18 years old Exclusion Criteria: * Prior surgery or radiotherapy to the area to be treated
Where it's running
-
Emory University Hospital Midtown
Atlanta, Georgia, United States Recruiting -
Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia, United States Recruiting
Study contacts
- Principal investigator: Mohammad K. Khan, MD, PhD, MS, FACRO, FACR, DABR — Emory University Hospital/Winship Cancer Institute
- Study coordinator: Mohammad K. Khan, MD, PhD, MS, FACRO, FACR, DABR
- Email: m.k.khan@emory.edu
- Phone: 404-778-3473
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Minibeam radiation with a tungsten slit collimator for recurrent or metastatic skin and superficial soft tissue tumors
This trial tests whether minibeam radiation delivered through a tungsten slit collimator is safe and what dose works best for adults with recurrent or metastatic skin or superficial soft tissue tumors.
-
Using a mobile app to monitor side effects of melanoma treatment
This study is testing a mobile app that helps people with melanoma track their symptoms while receiving treatment to see how well it works in managing side effects.
-
Combination of trastuzumab and pertuzumab for treating cancers with HER2 mutations
This study is testing if a combination of two cancer drugs, trastuzumab and pertuzumab, can help adults and young people with cancers that have HER2 mutations or amplifications.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.